(S (NP (JJ Monoclonal) (NNS antibodies)) (VP (VBP constitute) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (NNS strategies)) (SBAR (S (VP (TO to) (VP (VB treat) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NP (NNS cancers)) (PP (JJ such) (IN as) (NP (NP (JJ hematological) (NNS malignancies)) (CC and) (NP (JJ solid) (NNS tumors)))))))))))))))) (. .))
(S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB guarantee) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (DT those) (NNS preparations)) (VP (VBD prepared) (PP (IN at) (NP (NN hospital))))))))))) (, ,) (NP (NN quality) (NN control)) (VP (VBZ has) (S (VP (TO to) (VP (VB be) (VP (VBN developed)))))) (. .))
(S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB explore) (NP (NP (DT a) (ADJP (JJ noninvasive) (, ,) (JJ nondestructive) (, ,) (CC and) (JJ rapid)) (JJ analytical) (NN method)) (SBAR (S (VP (TO to) (VP (VB ensure) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (DT the) (JJ final) (NN preparation)))) (PP (IN without) (S (VP (VBG causing) (NP (NP (DT any) (NN delay)) (PP (IN in) (NP (DT the) (NN process)))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (CD four) (NN mAbs)) (PRN (-LRB- -LRB-) (NP (NNP Inlfiximab) (, ,) (NNP Bevacizumab) (, ,) (NNP Ramucirumab) (CC and) (NNP Rituximab)) (-RRB- -RRB-)) (VP (VBD diluted) (PP (IN at) (NP (JJ therapeutic) (NN concentration))) (PP (IN in) (NP (JJ chloride) (NN sodium) (CD 0.9) (NN %))))) (S (VP (VBG using) (NP (NNP Raman) (NN spectroscopy))))) (. .))
(S (S (VP (TO To) (VP (VB reduce) (NP (NP (DT the) (NN prediction) (NNS errors)) (VP (VBD obtained) (PP (IN with) (NP (JJ traditional) (JJ chemometric) (NN data) (NN analysis)))))))) (, ,) (NP (PRP we)) (VP (VBD explored) (NP (NP (DT a) (JJ data-driven) (NN approach)) (VP (VBG using) (NP (JJ statistical) (NN machine) (VBG learning) (NNS methods))) (SBAR (WHADVP (WRB where)) (S (NP (NN preprocessing) (CC and) (JJ predictive) (NNS models)) (VP (VBP are) (VP (ADVP (RB jointly)) (VBN optimized))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBD prepared) (NP (DT a) (NN data) (NNS analytics) (JJ workflow))) (CC and) (VP (VBD submitted) (NP (DT the) (NN problem)) (PP (TO to) (NP (NP (DT a) (JJ collaborative) (NN data) (NN challenge) (NN platform)) (VP (VBN called) (S (NP (NP (NNP Rapid) (NNPS Analytics) (CC and) (NNP Model) (NNP Prototyping)) (PRN (-LRB- -LRB-) (NP (NNP RAMP)) (-RRB- -RRB-))))))))) (. .))
(S (NP (DT This)) (VP (VBD allowed) (S (VP (TO to) (VP (VB use) (NP (NP (NNS solutions)) (PP (IN from) (NP (QP (IN about) (CD 300)) (NNS data) (NNS scientists)))) (PP (IN during) (NP (NP (CD five) (NNS days)) (PP (IN of) (NP (JJ collaborative) (NN work))))))))) (. .))
(S (NP (NP (DT The) (NN prediction)) (PP (IN of) (NP (DT the) (CD four) (NN mAbs) (NNS samples)))) (VP (VBD was) (VP (ADVP (RB considerably)) (VBN improved) (PP (IN with) (NP (NP (NP (DT a) (NN misclassification) (NN rate)) (CC and) (NP (DT the) (JJ mean) (NN error) (NN rate))) (PP (IN of) (NP (NP (NP (CD 0.8) (NN %)) (CC and) (NP (CD 4) (NN %))) (, ,) (ADVP (RB respectively)))))))) (. .))
